Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMA1(D12)-RON2L-TM mRNA-LNP vaccine
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
AMA1(D12)-RON2L-TM mRNA-LNP vaccine is a preclinical mRNA-lipid nanoparticle (LNP) vaccine candidate designed to target Plasmodium falciparum malaria. Developed by researchers at Johns Hopkins University, the National Institutes of Health (NIH), and the University of Victoria, the vaccine utilizes a structure-guided design to overcome the high antigenic polymorphism of Apical Membrane Antigen 1 (AMA1). The construct consists of AMA1 domains 1 and 2 (D12), with domain 3 eliminated to focus the immune response on neutralizing epitopes. It is fused to the RON2L peptide (a 49-amino acid region of Rhoptry Neck Protein 2, the parasite-derived binding partner of AMA1) to mimic the functional receptor-ligand complex and enhance the production of cross-neutralizing, strain-transcending antibodies. Additionally, the construct incorporates a transmembrane region (TM) for membrane anchoring, which enhances antibody titers and directs the immune response to the apical end of AMA1.
- Other names
- AMA1(D12)-RON2L-TM mRNA vaccineAMA1(D12)-RON2L-TM mRNA-LNPAMA1(D12)-RON2L-TM vaccine
02
Targets
AMA1 (Apical membrane antigen 1)RON2 (Rhoptry neck protein 2)
Beyond the preview
Go deeper on AMA1(D12)-RON2L-TM mRNA-LNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMA1(D12)-RON2L-TM mRNA-LNP vaccine.